Article info

Olokizumab, a monoclonal antibody against interleukin 6, in combination with methotrexate in patients with rheumatoid arthritis inadequately controlled by methotrexate: efficacy and safety results of a randomised controlled phase III study

Authors

  1. Correspondence to Dr Mark Genovese, Division of Immunology and Rheumatology, Stanford University, Stanford, California, USA; genovese{at}stanford.edu
View Full Text

Citation

Nasonov E, Fatenejad S, Feist E, et al
Olokizumab, a monoclonal antibody against interleukin 6, in combination with methotrexate in patients with rheumatoid arthritis inadequately controlled by methotrexate: efficacy and safety results of a randomised controlled phase III study

Publication history

  • Received January 18, 2021
  • Accepted July 5, 2021
  • First published August 3, 2021.
Online issue publication 
October 18, 2023

Article Versions

  • Supplementary Data

    This web only file has been produced by the BMJ Publishing Group from an electronic file supplied by the author(s) and has not been edited for content.

Request permissions

If you wish to reuse any or all of this article please use the link below which will take you to the Copyright Clearance Center’s RightsLink service. You will be able to get a quick price and instant permission to reuse the content in many different ways.